secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2023-04-14T23:59:59+00:00
Accession:  0001104659-23-045300
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode enters $1.08M equity line with White Lion Capital for TTX-MC138 development
--------------------------------------------------------------------------------

- Up to $1.08M in common stock purchase agreement with White Lion Capital; proceeds for working capital and TTX-MC138 development.
- Purchase price set at 92% of lower of 2-day VWAP or lowest closing price during valuation period.
- Commitment period ends May 31, 2023; if less than 1.5M shares sold by then, company must deliver shares to White Lion.
- Exchange cap of 3,163,124 shares (19.99% of outstanding) unless average price >= $0.39 or stockholder approval.
- Shares offered under effective shelf registration statement (File No. 333-268764).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923045300/0001104659-23-045300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923045300/tm2312650d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-045300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer